

Supplemental Table 1: A summary of NY-ESO-1 specific CD4+ and CD8+ T-cell responses. All patients were monitored pre and post vaccination in ELISPOT assays after presensitization of effector cells with NY-ESO-1 peptide pools, and in addition, with NY-ESO-1 p157-165 in HLA-A2+ patients. On day 10-12, a number of 18-20mer overlapping peptides were pulsed on autologous APC (dendritic cells, EBV-B-cells) and used as targets. In addition, in HLA-A2 patients, NY-ESO-1 p157-165 was pulsed on T2 cells and used as target. Pre and post-vaccine results were shown in numbers of spots/25000 CD4 and CD8 T-cells detected on peptide-pulsed or unpulsed target APC.

Supplemental Figure 1: Trial design schema

Supplemental Figure 2: In-vitro immunostimulatory activity of MBV on PBMC

Supplemental Figure 3: In-vitro activity of MBV on DC

Supplemental Figure 4: Reactivation of cytokine response by further MBV administration after a MBV treatment-free period